Dr. McFarland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 S Park St
Madison, WI 53715Phone+1 608-287-2552Fax+1 608-287-2781
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
- Tufts Medical CenterResidency, Internal Medicine, 1987 - 1990
- University of Illinois College of MedicineClass of 1987
Certifications & Licensure
- IL State Medical License 2017 - 2026
- WI State Medical License 1994 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Start of enrollment: 2014 Jun 13
Publications & Presentations
PubMed
- 27 citationsPilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanomaMark R. Albertini, Richard K. Yang, Erik A. Ranheim, Jacquelyn A. Hank, Cindy L. Zuleger
Cancer Immunology, Immunotherapy. 2018-08-03 - 11 citationsVcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.Julie E. Chang, Lakeesha Carmichael, KyungMann Kim, Christopher Peterson, David T. Yang
Clinical Lymphoma, Myeloma & Leukemia. 2018-01-01 - 19 citationsA phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.Mark Agulnik, Ricardo Costa, Mohammed M. Milhem, Alfred Rademaker, B. C. Prunder
Annals of Oncology. 2017-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: